File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

TitleA Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
Authors
Tu, HYFeng, JShi, MZhao, JWang, YChang, JWang, JCheng, YZhu, JTan, EHLi, KZhang, YLee, VYang, CTSu, WCLam, CLDSrinivasa, BJRajappa, SHo, CLLam, KCHu, YBondarde, SALiu, XTian, YXue, ZCseh, AHuang, DCZhou, CWu, YL
Issue Date2022
Citation
Targeted Oncology, 2022, v. 17, p. 1-13 How to Cite?
DOI: http://dx.doi.org/10.1007/s11523-021-00859-6
Persistent Identifierhttp://hdl.handle.net/10722/322285
ISI Accession Number ID
WOS:000741895100001

 

DC FieldValueLanguage
dc.contributor.authorTu, HY-
dc.contributor.authorFeng, J-
dc.contributor.authorShi, M-
dc.contributor.authorZhao, J-
dc.contributor.authorWang, Y-
dc.contributor.authorChang, J-
dc.contributor.authorWang, J-
dc.contributor.authorCheng, Y-
dc.contributor.authorZhu, J-
dc.contributor.authorTan, EH-
dc.contributor.authorLi, K-
dc.contributor.authorZhang, Y-
dc.contributor.authorLee, V-
dc.contributor.authorYang, CT-
dc.contributor.authorSu, WC-
dc.contributor.authorLam, CLD-
dc.contributor.authorSrinivasa, BJ-
dc.contributor.authorRajappa, S-
dc.contributor.authorHo, CL-
dc.contributor.authorLam, KC-
dc.contributor.authorHu, Y-
dc.contributor.authorBondarde, SA-
dc.contributor.authorLiu, X-
dc.contributor.authorTian, Y-
dc.contributor.authorXue, Z-
dc.contributor.authorCseh, A-
dc.contributor.authorHuang, DC-
dc.contributor.authorZhou, C-
dc.contributor.authorWu, YL-
dc.date.accessioned2022-11-14T08:18:59Z-
dc.date.available2022-11-14T08:18:59Z-
dc.date.issued2022-
dc.identifier.citationTargeted Oncology, 2022, v. 17, p. 1-13-
dc.identifier.urihttp://hdl.handle.net/10722/322285-
dc.languageeng-
dc.relation.ispartofTargeted Oncology-
dc.titleA Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China-
dc.typeArticle-
dc.identifier.emailLam, CLD: dcllam@hku.hk-
dc.identifier.authorityLam, CLD=rp01345-
dc.identifier.doi10.1007/s11523-021-00859-6-
dc.identifier.hkuros341729-
dc.identifier.volume17-
dc.identifier.spage1-
dc.identifier.epage13-
dc.identifier.isiWOS:000741895100001-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats